Our top pick for
Building a portfolio
Exelixis, Inc (EXEL) is a leading biotechnology business based in the US. It opened the day at USD$22.17 after a previous close of USD$22.21. During the day the price has varied from a low of USD$21.99 to a high of USD$22.44. The latest price was USD$22.37 (25 minute delay). Exelixis is listed on the NASDAQ and employs 773 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Exelixis's share price has had significant positive movement.
Its last close price was USD$22.37, which is 5.72% up on its pre-crash value of USD$21.09 and 63.64% up on the lowest point reached during the March crash when the shares fell as low as USD$13.67.
If you had bought USD$1,000 worth of Exelixis shares at the start of February 2020, those shares would have been worth USD$877.60 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,279.79.
|52-week range||USD$17.54 - USD$27.8|
|50-day moving average||USD$22.5663|
|200-day moving average||USD$21.9388|
|Wall St. target price||USD$31.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.35|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Exelixis shares trade at around 67x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1967. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$121.9 million.
The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$987.5 million|
|Operating margin TTM||11.42%|
|Gross profit TTM||USD$954 million|
|Return on assets TTM||3.5%|
|Return on equity TTM||6.27%|
|Market capitalisation||USD$7.3 billion|
TTM: trailing 12 months
There are currently 13.3 million Exelixis shares held short by investors – that's known as Exelixis's "short interest". This figure is 5.2% up from 12.6 million last month.
There are a few different ways that this level of interest in shorting Exelixis shares can be evaluated.
Exelixis's "short interest ratio" (SIR) is the quantity of Exelixis shares currently shorted divided by the average quantity of Exelixis shares traded daily (recently around 1.9 million). Exelixis's SIR currently stands at 7.17. In other words for every 100,000 Exelixis shares traded daily on the market, roughly 7170 shares are currently held short.
However Exelixis's short interest can also be evaluated against the total number of Exelixis shares, or, against the total number of tradable Exelixis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exelixis's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Exelixis shares in existence, roughly 40 shares are currently held short) or 0.0481% of the tradable shares (for every 100,000 tradable Exelixis shares, roughly 48 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Exelixis.
Find out more about how you can short Exelixis stock.
We're not expecting Exelixis to pay a dividend over the next 12 months.
Over the last 12 months, Exelixis's shares have ranged in value from as little as $17.54 up to $27.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 1.0452. This would suggest that Exelixis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.